Definitive Concurrent Hypofractionated Rth With Weekly Cisplatin in Locally Advanced SCCHN

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

62 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-03-10

Study Completion Date

2020-12-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary endpoint will be acute toxicity. Secondary endpoints included: late toxicity and quality of life; loco-regional control, disease free survival and overall survival.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Concurent Chemoradiotherapy in Head and Neck Cancers

NCT04780750

Squamous Cell Carcinoma of Head and Neck

UNKNOWN PHASE3

Cisplatin Chemoradiation With or Without Cetuximab for Locoregionally Advanced Squamous Cell Carcinomas (SCC) of the Head and Neck

NCT01301248

Head and Neck Neoplasms AJCC Stage III/IV

UNKNOWN PHASE2

Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)

NCT00357149

Head and Neck Neoplasms

COMPLETED PHASE2

Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers

NCT02994069

Carcinoma, Squamous Cell Head and Neck Cancer

ACTIVE_NOT_RECRUITING PHASE2

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

NCT05050162

Advanced Head and Neck Squamous Cell Carcinoma Advanced Hypopharyngeal Squamous Cell Carcinoma Advanced Laryngeal Squamous Cell Carcinoma +7 more

SUSPENDED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Head and neck cancer is considered the 6th most common cancer all over the world, with 890,000 new cases and 450,000 deaths in 2018 (1). The histologic type in more than 90% of head and neck cancer is squamous cell carcinoma (SCC) (2). The incidence of SCC in head and neck (SCCHN) continues to rise and is expected to increase by 30% in 2030, which means about 1.08 million new cases annually (3). Hospital-based studies in Egypt showed that SCCHN represents about 20% of all malignancies. The overall incidence of SCCHN in Egypt from 1999 to 2006 was approximately twice among males (476,000) than in females (273,000) (4). Males are affected significantly more than females, with a ratio ranging from 2:1 to 4:1 (5).

Tobacco and alcohol consumption are the high-risk factors of SCCHN (6). Human papilloma virus (HPV), especially subtypes 16 and 18 are implicated risk factors in oropharyngeal cancer (7). Some studies found an association between HPV and P53 gene mutation, as HPV expresses two viral proteins (E6 and E7 proteins) that inactivates P53 and pRB genes, causing genomic instability and malignant transformation ((8)). SCCHN arises from the mucosal epithelium of the oral cavity, nasopharynx, oropharynx, hypopharynx, and larynx. HPV associated SCCHN arises primarily from the palatine and lingual tonsils of the oropharynx, whereas tobacco associated SCCHN arises primarily in the oral cavity, hypopharynx, and larynx.

SCCHN is being increasingly treated by multimodality approaches combining surgery, radiotherapy (RT), and chemotherapy (CTH). Randomized controlled trials have demonstrated major improvements in loco-regional tumor control (LRC) from altered fractionation RT with CTH as compared with conventional fractionated RT (CFRT) (9). Altered fractionation schedules reduces tumor repopulation effect and seek to improve the therapeutic ratio between tumor cell killing and normal tissue damage. Additionally, some data showed that cancer patients are at higher risk of COVID-19 infection comparing with the general population due to many treatment visits, so hypo-RT schedules are better for these patients. hypo-RT utilizes a small number of fractions with a larger dose per fraction (\> 2Gy per fraction), shortening overall treatment time compared to a CFRT (9). Although a shorter treatment time can be obtained by applying a higher dose per fraction, it might also result in an increase in the incidence of late complications.

The aim of this study was to investigate hypo fractionated intensity modulated RT (hypo-IMRT) with 62.5 Gy in 25 daily fractions over five weeks (2.5 Gy per fraction with weekly cisplatin 40mg/m2 in patients with high-risk stage II (T2N0, excluding glottic laryngeal) disease, stage III (T1-3 N1 or T3N0) and stage IV (T1-4N2 orN3). The primary endpoint will be assessment of acute toxicity. Secondary endpoints included: late toxicity and quality of life; LRC, disease free survival (DFS) and overall survival (OS).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Squamous Cell Carcinoma of the Head and Neck

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

hypofractionated Rth with weekly cisplatin 40mg/m2

hypofractionated radioyherapy with weekly cisplatin 40mg/m2

hypofractionated Rth with platinol

Intervention Type RADIATION

hypofractionated Rth with weekly cisplatin 40mg/m2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

hypofractionated Rth with platinol

hypofractionated Rth with weekly cisplatin 40mg/m2

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have histologically or cytologically proven oropharyngeal, laryngeal or hypopharyngeal squamous cell carcinoma; with AJCC high risk stage II (T2N0, excluding glottic laryngeal) disease, stage III (T1-3N1 or T3N0) and stage IV (T1-4N2 or N3) Locally advanced non metastatic stage II/IV SCCHN according to AJCC stage classification 2018 (8th edition);
* Age \>18 years and \<75 years;
* No previous treatment(neither chemotherapy nor radiotherapy);
* Eastern Cooperative Oncology Group(ECOG) performance status of \<2;
* Adequate organ function;
* Provide informed oral or written consent.

Exclusion Criteria

* prior surgical curative resection for primary tumor;
* patients with metastatic disease;
* prior radiotherapy within the treatment field;
* any relative contraindication to radiotherapy;
* prior administration of EGFR monoclonal antibodies, signal transduction inhibitors or targeted therapies;
* Active severe infection;
* Active concomitant malignancy;
* Pregnant and or lactating women;
* Pre-existing motor or sensory neurotoxicity \> CTCAE grade 2.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes